Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Phase III CHAPTER-3 results for deucrictibant XR in HAE show attack rates reduced 83% versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. Therapy was well-tolerated and improved quality of life.
PHVS says its Phase 3 CHAPTER-3 trial showed deucrictibant XR 40 mg once daily reduced hereditary angioedema attack rates by 83% versus placebo, with rapid onset, sustained effect, improved quality of life, and a favorable safety profile.